2023年6月13日

新闻分享这篇文章分享这篇文章提供的多伦多,6月13日2023 / DAMONA从制药、临床生物制药公司专注于first-in-class小分子的发现和发展认知症状的治疗和预防与脑部疾病和衰老有关,今天宣布任命约翰•赖利为公司的首席执行官和董事会成员。首席执行官约翰·赖利是新的DAMONA制药赖利先生带来了二十年的领导经验建设和为生物技术公司创造价值,与深度知识和技能在企业战略、业务发展和领导团队在临床前研发和临床发展的创新疗法。“我们感到非常幸运,吸引了约翰为Damona首席执行官的角色。他带来丰富的生物技术偏好经验和大量的北美投资者和合作伙伴的关系网络,这将是必不可少的在我们的领先优势资产向印第安纳州和临床人体概念验证试验,“艾蒂安Sibille博士说,DAMONA的联合创始人和首席科学家。“我欣喜若狂约翰加入DAMONA团队担任CEO。约翰带来了一个伟大的背景DAMONA那些被证明有记录的建立和管理高性能临床前和临床生物制药团队交付结果,”雅Jenuth说Lumira合资企业的合作伙伴和首席运营官。加入DAMONA之前,赖利先生共同担任总裁兼首席执行官Apic生物,基因疗法公司发展first-in-class治疗罕见的神经系统和肝脏疾病。Apic,他获得了多个资金,监督开发项目,并策划一个全球许可协议与uniQure公司的领导计划治疗超氧化物歧化酶1 (SOD1),一种罕见的、遗传形式的肌萎缩性侧索硬化症。以前,赖利先生举行了高级管理职位的数量在不同的生物制药公司,包括Tetragenetics业务发展副总裁,这被Abcellera收购(纳斯达克:ABCL)。Tetragenetics之前,他创办并担任首席执行官Gendyne疗法。 Mr. Reilly holds a B.A. from Hamilton College and M.S. and M.B.A. degrees from Cornell University. "I am very excited to join DAMONA as CEO and look forward to working with the board, management, and scientific team to continue the company's impressive progress as we advance the preclinical pipeline and lead program for the treatment of cognitive symptoms associated with depression and diseases of aging into a Phase 1 clinical study," said John Reilly, CEO of DAMONA Pharmaceuticals. About DAMONA Pharmaceuticals DAMONA is a privately held preclinical biopharmaceutical company developing small molecule therapeutics that transform the treatment of cognitive deficits and restore normal brain functions for underserved and understudied mental health conditions and for aging populations. DAMONA was founded by Etienne Sibille, Ph.D., and the Centre for Addiction and Mental Health (CAMH). In 2022, DAMONA closed a seed financing round co-led by Lumira Ventures and the Noetic Fund. For more information, please visit: www.damonapharma.com . Contact: